Overview

Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The aim of our study is to evaluate if the use of a precision-medicine approach with a specific therapy tailored on the underlying pathogenic mechanism will improve the quality-of-life in MINOCA patients. The investigators further aim at investigating wherever a precision-medicine approach will improve the prognosis, healthcare related costs, and if that a different profile of plasma biomarkers and microRNAs may serve as diagnostic tools for detecting specific causes of MINOCA and to assess response to therapy. Finally, beyond its pivotal role in differential diagnosis, the investigators hypothesize that cardiac magnetic resonance (CMR) may provide a morphological and functional cardiac characterization as well as help in the prognostic stratification.
Phase:
Phase 4
Details
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators:
Centro Cardiologico Monzino
IRCCS Policlinico S. Donato
Treatments:
Acetylcholine
Adrenergic beta-Antagonists
Anticoagulants
Platelet Aggregation Inhibitors